Highlights
- •Many risk factors of acute pancreatitis have been well established.
- •Only few cases of acute pancreatitis were reported to be possibly related to sitagliptin use.
- •No significant association is detected between sitagliptin use and acute pancreatitis.
Abstract
Background
There is still lack of definite evidence to establish the association between sitagliptin
use and acute pancreatitis. The study aimed to test this issue in Taiwan.
Methods
This case-control study was designed to analyze the database of the Taiwan National
Health Insurance Program. There were 349 subjects with type 2 diabetes mellitus aged
20–84 with a first-attack of acute pancreatitis from 2009 to 2011 as the case group
and 1116 randomly selected subjects with type 2 diabetes mellitus without acute pancreatitis
as the control group. Both groups were matched with sex, age, comorbidities, and index
year of diagnosing acute pancreatitis. Current use of sitagliptin was defined as subjects
who had their last tablet of sitagliptin ≤7 days before the date of diagnosing acute pancreatitis. Late use of sitagliptin was
defined as subjects who had their last tablet of sitagliptin between 8 and 30 days before the date of diagnosing acute pancreatitis. Never use of sitagliptin was
defined as subjects who never had a sitagliptin prescription. The risk of acute pancreatitis
associated with sitagliptin use was estimated by the odds ratio (OR) and 95% confidence
interval (CI) using the multivariable logistic regression model.
Results
After statistical correction for potential confounders, the adjusted OR of acute pancreatitis
was 2.47 for subjects with current use of sitagliptin (95% CI 0.84, 7.28), when compared
with those never using sitagliptin, but without statistical significance. The adjusted
OR decreased to 1.14 for subjects with late use of sitagliptin (95% CI 0.66, 1.98),
but without statistical significance.
Conclusions
No significant association is detected between sitagliptin use and acute pancreatitis
in type 2 diabetes mellitus.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis.BMC Endocr Disord. 2008; 8: 14
- Safety of dipeptidyl peptidase 4 inhibitors: a perspective review.Ther Adv Drug Saf. 2014; 5: 138-146
- Sitagliptin-asso-ciated acute pancreatitis: a case report.J Intern Med Taiwan. 2011; 22: 278-282
- Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide.Endocr Pract. 2012; 18: e10-e13
- eHealthMe study from FDA and social media reports. Review: could sitagliptin phosphate cause acute pancreatitis?.([cited in 2014 november])
- National Health Insurance Research Database. Taiwan.([cited in 2015 September] [English version])
- Polypharmacy correlates with increased risk for hip fracture in the elderly: a population-based study.Medicine (Baltimore). 2010; 89: 295-299
- Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study.Am J Gastroenterol. 2012; 107: 46-52
- Diabetes mellitus correlates with increased risk of pancreatic cancer: a population-based cohort study in Taiwan.J Gastroenterol Hepatol. 2012; 27: 709-713
- Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.Clin Pharmacol Ther. 2005; 78: 675-688
- Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.Diabetes Obes Metab. 2010; 12: 648-658
- Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide.Curr Med Res Opin. 2009; 25: 1019-1027
- Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis.Diabetes Care. 2010; 33: 2349-2354
- Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.Int J Clin Pract. 2010; 64: 984-990
- Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study.BMJ. 2013; 346: f2267
- Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study.BMJ. 2014; 348: g2780
- Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study.Lancet Diabetes Endocrinol. 2014; 2: 111-115
- Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.BMJ. 2014; 348: g2366
- Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials.Diabetes Obes Metab. 2014; 16: 48-56
- Effect of sitagliptin on cardiovascular outcomes in Type 2 diabetes.N Engl J Med. 2015; 373: 232-242
- Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.JAMA Intern Med. 2013; 173: 534-539
- Drug-induced pancreatitis.Curr Gastroenterol Rep. 2012; 14: 131-138
- Pyogenic liver abscess correlates with increased risk of acute pancreatitis: a population-based cohort study.J Epidemiol. 2015; 25: 246-253
- Chronic osteomyelitis correlates with increased risk of acute pancreatitis in a case-control study in Taiwan.Eur J Intern Med. 2015; 26: 429-432
- Nationwide population science: lessons from the Taiwan National Health Insurance Research Database.JAMA Intern Med. 2015; 175: 1527-1529
- Risk of acute pancreatitis in type 2 diabetes and risk reduction on anti-diabetic drugs: a population-based cohort study in Taiwan.Am J Gastroenterol. 2011; 106: 1697-1704
- Amiodarone use and risk of acute pancreatitis: a population-based case-control study.Heart Rhythm. 2015; 12: 163-166
- Actively using clopidogrel correlates with an increased risk of acute pancreatitis in Taiwan.Int J Cardiol. 2015; 183: 263-266
Article info
Publication history
Published online: September 30, 2015
Accepted:
September 21,
2015
Received in revised form:
September 20,
2015
Received:
June 25,
2015
Identification
Copyright
© 2015 European Federation of Internal Medicine. Published by Elsevier Inc. All rights reserved.
